Association between myeloperoxidase levels and risk of coronary artery disease.

By Renliang Zhang, M. Brennan, Xiaoming Fu, Ronnier J. Aviles, G. Pearce, M. Penn, Eric J. Topol, D. Sprecher, Stanley L Hazen. Journal of the American Medical Association (JAMA), 2001

984 citations recorded by the source corpus.

Subfields: Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/6c46b56773c92aaa7903013fe4f4477979f8b99c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Peter Libby
2. Christian Weber
3. J. Keaney
4. S. Klebanoff
5. A. Zernecke
6. G. Hansson
7. P. Ridker

In Physiology

1. Peter Libby
2. K. Sugamura
3. S. Klebanoff
4. J. Keaney

Citations in the corpus

• Reactive Oxygen Species in Cardiovascular Disease (2011, background): “Leukocyte MPO levels are associated with the extent of coronary atherosclerosis [155] and circulating MPO levels are a good indicator of the presence and extent of coronary artery disease (CAD) [156, 157].”
• Biological markers of oxidative stress: Applications to cardiovascular research and practice (2013, background): “The term biomarker has been defined by The National Institutes of Health as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention” [1].”
• Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. (2003, result): “This hypothesis is supported by a recent study, which has shown that elevated leukocyte count and blood MPO levels are associated with the presence of coronary artery disease in a group of non-renal patients [32].”
• Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. (2004, background): “Plasma, serum, and leukocyte MPO levels have now been associated with angiographic evidence of coronary artery disease (32); incident risk of myocardial infarction, death, and need for revascularization (33, 34); and enhanced endothelial dysfunction (83).”
• Insulin resistance and chronic cardiovascular inflammatory syndrome. (2003, positive): “Myeloperoxidase, an enzyme principally associated with host defense mechanisms, has also been associated with CRP levels and cardiovascular risk (313).”
• The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models (2008, background): “In addition, myeloperoxidase activity and plasma levels are increased in patients with a genetic polymorphism in the myeloperoxidase gene, MPO , and are associated with cardiovascular diseas”
• Myeloperoxidase: friend and foe (2005, background): “Neutrophil MPO levels were significantly higher in patients with coronary heart disease than in normal controls [475].”
• Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. (2004, background): “Examples from other popular journals are Ridker et al. (11), Zhang et al. ( 12 ), Liou et al. (13), and Hogue et al. (14).”